Manufacturing of a Prothrombin Complex Concentrate Aiming at Low Thrombogenicity

Josić, Djuro; Hoffer, Lutz; Buchacher, Andrea; Schwinn, Horst; Frenzel, Wolfgang; Biesert, Lothar; Klöcking, H.-P.; Hellstern, Peter

doi:10.1016/s0049-3848(00)00339-x

Cited by 40 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If FFP's are not feasible due to concerns of fluids overload, non-activated prothrombin complex concentrate (PCC) may be administered at 25-30 U/kg dose (66) . Since this concentrate, contains only Vitamin K dependent factors it will replace the deficit partially.…”

Section: Replacement Of Blood and Blood Productsmentioning

confidence: 99%

Disseminated Intravascular Coagulation in Obstetrics: Ethiopathogenesis and up to date Management Strategies

Şahin¹,

Eroğlu²,

Tetik³

et al. 2014

J Turk Soc Obstet Gynecol

View full text Add to dashboard Cite

show abstract

Section: Replacement Of Blood and Blood Productsmentioning

confidence: 99%

Disseminated Intravascular Coagulation in Obstetrics: Ethiopathogenesis and up to date Management Strategies

Şahin¹,

Eroğlu²,

Tetik³

et al. 2014

J Turk Soc Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…Se trata de un CCP de segunda generación (4 factores), que optimiza el proceso inactivación viral utilizando la combinación de nanofiltración y tratamiento con solvente/detergente, y que incluye proteínas anticoagulantes naturales (proteínas C y S) para proporcionar un balance hemostático adecuado 6,7 . Cada ml de octaplex® contiene factor II (11-38 UI), factor VII (9-24 UI), factor IX (20-30 UI) y factor X (18-30 UI).…”

Section: Pacientes Y Métodosunclassified

Seguridad y eficacia de un concentrado de complejo protrombínico en pacientes con coagulopatía y hemorragia

Martínez‐Calle

Marcos-Jubilar

Alfonso

et al. 2014

Anales Sis San Navarra

View full text Add to dashboard Cite

“…PCC is a heterogeneous mixture of the vitamin K dependent plasma clotting factors, including II, VII, IX, X, and protein C and S, derived from large donor plasma pools by ion-exchange chromatography and cryoprecipitation (Table 1) [31,32].…”

Section: Composition Of Pccmentioning

confidence: 99%

“…The early PCC products contained three clotting factors, II, IX, and X; however, some of the newer formulations, available in some European countries, but not the United States are deemed ''four factor concentrates'' as they also contain factor VII in a significant concentration [31,32]. Additionally, some PCC formulations contain protein C and S, protein Z, antithrombin III, and/or heparin.…”

Section: Composition Of Pccmentioning

confidence: 99%

Prothrombin Complex Concentrates for Oral Anticoagulant Therapy-Related Intracranial Hemorrhage: A Review of the Literature

Bershad

Suárez

2009

Neurocrit Care

View full text Add to dashboard Cite

Warfarin-related intracranial hemorrhage carries a high mortality and poor neurological outcome. Rapid reversal of coagulopathy is a cornerstone of medical therapy to halt bleeding progression; however the optimal approach remains undefined. Prothrombin complex concentrates have promising features that may rapidly reverse coagulopathy, but remain relatively unstudied. We aim to review the literature regarding the use of prothrombin complex concentrates in patients with warfarin-related intracranial hemorrhage. A comprehensive review of the literature was conducted using PUBMED and Google Scholar databases to identify the use of PCC in patients with warfarin-related intracranial hemorrhage. The characteristics abstracted included the type of PCC, dosing, study design, type of intracranial hemorrhage, changes in the INR, and adverse effects. Prothrombin complex concentrates are heterogeneous in regards to factor concentration. PCC consistently reversed the INR in patients with intracranial hemorrhage. There is some evidence that PCC may reverse the INR more rapidly compared to fresh frozen plasma. Serious adverse effects were uncommon and included mainly thromboembolism. PCC has features which make it a promising therapy for patients with warfarin-related intracranial hemorrhage, and deserves more rigorous study in prospective-randomized controlled trials.

show abstract

Manufacturing of a Prothrombin Complex Concentrate Aiming at Low Thrombogenicity

Cited by 40 publications

References 18 publications

Disseminated Intravascular Coagulation in Obstetrics: Ethiopathogenesis and up to date Management Strategies

Disseminated Intravascular Coagulation in Obstetrics: Ethiopathogenesis and up to date Management Strategies

Seguridad y eficacia de un concentrado de complejo protrombínico en pacientes con coagulopatía y hemorragia

Prothrombin Complex Concentrates for Oral Anticoagulant Therapy-Related Intracranial Hemorrhage: A Review of the Literature

Contact Info

Product

Resources

About